All posts by admin

CMS Quality Payment Program Updates

By | Latest Oncology News | No Comments

CMS QUALITY PAYMENT PROGRAM The Medicare Access and CHIP Reauthorization Act (MACRA) repealed the Sustainable Growth Rate (SGR) formula for physician payments and introduced a new Medicare value-based reimbursement system. The new system, the Medicare Quality Payment Program (QPP), has two tracks that providers will choose from, the Advanced Alternative Payment Models (APMs) or the Merit-based Incentive Payment System (MIPS). Providers who are subject to the QPP include physicians, physician assistants (PAs), nurse practitioners (NPs), clinical nurse specialists (CNSs), and certified registered nurse anesthetists (CRNAs). Providers that are new to Medicare, and those that meet a low-volume threshold are exempt from MIPS this year as are certain providers participating in an APM. Earlier this month, the Centers for Medicare & Medicaid Services (CMS) released an online lookup tool through which providers can determine their participation status in the Merit-based Incentive Payment System (MIPS) by entering their 10-digit National Provider Identifier…

Read More

Fraud and Abuse Initiatives

By | Latest Oncology News | No Comments

In the current political environment, the future of the Affordable Care Act and other health care initiatives is likely to look very different than they do now. However, two initiatives are expected to continue, the movement toward value-based payments, and audits to prevent and recover improper payments. The Q1 2017 Oplinc Best Practices Review Newsletter looks at some of the current health care fraud and abuse programs and discuss what you can do to prepare your practice. Access this newsletter by clicking on Oplinc’s Best Practices Review Newsletter Archive.

Read More

Medicare Updates

By | Latest Oncology News | No Comments

OBAMA ADMINISTRATION HALTS PART B DRUG MODEL On Thursday, December 15, the Obama administration announced that the proposed Medicare Part B Drug Model would not move forward at this time. The decision to halt the program came after much criticism, for the scope and design of the program, from public comments on the proposed rule to a letter signed by more than 170 members of the House to CMS and the Centers for Medicare & Medicaid Innovation (CMMI). In their letter, the congressional members state that CMMI models should be implemented in a voluntary, limited-scale basis, and that the CMMI has exceeded its authority with the development of the mandatory Part B Drug Payment Model. In a statement explaining the decision to halt the proposed program, a CMS spokesperson said, “While CMS was working to address these concerns, the complexity of the issues and the limited time available led to…

Read More

CMS Releases 2017 Physician Fee Schedule Final Rule

By | Latest Oncology News | No Comments

On Wednesday, November 2, 2016, CMS released the 2017 Physicians Fee Schedule Final Rule. This final rule updates payment policies, payment rates and other provisions for services furnished under the Medicare Physician Fee Schedule. The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) calls for a conversion factor (CF) increase of 0.5% from 2016 – 2019. However, the 2017 CF is also impacted by the Achieving a Better Life Experience (ABLE) Act of 2014. The ABLE Act sets a target for adjustments to misvalued codes in the fee schedule of 1.0% for 2016, and 0.5% for 2017 and 2018. In the 2017 final rule, CMS finalized misvalued code changes achieving a 0.32% net expenditure reduction. This does not meet the misvalued code target of 0.5% for 2017. Therefore, as required under the ABLE Act, CMS must apply a reduction of equal to the percentage difference between the target 0.5%…

Read More

CMS Releases Final Rule on MACRA, MIPS & APMs

By | Latest Oncology News | No Comments

On October 14, 2016, CMS issued the Final Rule that implements the Medicare Access and CHIP Reauthorization Act (MACRA). The final rule, Medicare Program; Merit-based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models, provides details on the first year implementation of the new Quality Payment Program (QPP) and the two paths eligible clinicians will choose from: Advanced Alternative Payment Models (Advanced APMs) and the Merit-based Incentive Payment System (MIPS). In response to commenters concerns and suggestions, the final rule, released on October 14, includes some significant changes from the proposed rule. The first payment year for MIPS is 2019 and will be based on the 2017 MIPS performance. Acknowledging commenters concerns that eligible clinicians will not be ready by January 1, 2017 to report under MIPS, CMS has developed 3 options for participation in the MIPS path…

Read More

CMS Issues New CPT Code for Billing Prolonged Drug and Biological Infusions Using an External Ambulatory Infusion Pump

By | Latest Oncology News | No Comments

MLN Matters® Number MM9749 CMS Issues New CPT Code for Billing Prolonged Drug and Biological Infusions Using an External Ambulatory Infusion Pump On August 19, 2016 CMS published MLN Matters® Number MM9749 which states that CMS has established a new code G0498 for billing the ambulatory infusion pumps used in extended IV infusions. CMS is directing all Medicare MACs to load the new code. Code: G0498 Long Descriptor: Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/other outpatient setting using office/other outpatient setting pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/other outpatient setting, includes follow up office/other outpatient visit at the conclusion of the infusion. MLN MM9749 states that G0498 is effective for dates of service on or after January 1, 2016. G0498 has a procedure status of “C”; codes…

Read More

CMS Releases Clarification on Billing for Prolonged Infusion Services

By | Latest Oncology News | No Comments

MLN Matters® Number: SE1609 Medicare Policy Clarified for Prolonged Drug and Biological Infusions Started Incident to a Physician’s Service Using an External Pump   On Friday, April 29, CMS released MLN Matters® Number SE1609, which they describe as a clarification. In fact, the clarification outlined in this MLN Matters Special Edition article fundamentally changes our understanding for billing external infusion pumps that are initiated in the HOPD or physician office and sent home with the patient for the remainder of the CIV infusion of the drug or biological. In the past, the rules for billing for these services and the drugs provided via the ambulatory infusion pump have been a bit confusing as the direction provided from the DME MAC and the Part B MAC were often at odds. The CMS MLN Matters article was published in response to the confusion between the DME and Part B MACs and their…

Read More

CMS Proposes New Part B Drug Payment Model

By | Latest Oncology News | No Comments

On February 5th, the Centers for Medicare & Medicaid Services (CMS) posted and then removed a transmittal to Medicare contractors that outlined a new payment model to be tested for Part B drugs. Transmittal 137, Change Request 9501 was to have an effective date of July 1, 2016 and an implementation date of July 5, 2016. This transmittal instructed Medicare Administrative Contractors (MACs) and other Medicare shared system maintainers, to put in place the necessary system changes to implement the Part B Drug Payment Model which would consist of the testing of different Average Sales Price (ASP) payment limit values in certain defined geographic areas based on ZIP code. Details of what the changes to ASP would be or exactly how they will be applied were not provided in the transmittal. However, CMS did state that they would also test the impact of targeted pricing changes to payments for individual Part B drugs beyond…

Read More

Congress Passes Permanent SGR Fix

By | Latest Oncology News | No Comments

Late last night, the Senate passed H.R. 2, the “Medicare Access and Chip Reauthorization Act,” (MACRA), by a vote of 92-8. This bill is the same bill that was passed by the House on March 26 by a vote of 392-37.The bill now goes to President Obama for his signature. President Obama has previously indicated he would sign the bill. Medicare payments will remain at the rate that was effective prior to the April 1 deadline until July 1, 2015 at which time the fee schedule conversion factor will be increased by 0.5%. Among the bill’s significant provisions: Replaces the SGR with an increase of 0.5% in Medicare physician reimbursement starting in July 2015 through December 2015, and then annual 0.5% increases lasting through 2019 Consolidates reporting programs, such as the Meaningful Use program for electronic health records and several quality reporting programs, into a new, merit-based incentive payment system,…

Read More

ICD-10 Update & Payment Reform Proposal

By | Latest Oncology News | 8,036 Comments

5/5/2014 CMS PUBLISHES STATEMENT ON ICD-10 IMPLEMENTATION & TESTING On Friday, May 2, the Centers for Medicare and Medicaid Services (CMS) issued a MLN Connects™ Provider eNews Special Edition with information on the new ICD-10 implementation date and the previously scheduled ICD-10 end-to-end testing. The Protecting Access to Medicare Act of 2014 implemented on April 1, 2014, includes a provision that the U.S. Department of Health and Human Services Secretary may not adopt ICD-10 prior to October 1, 2015. Friday, CMS published the Special Edition MLN eNews article stating that they would release an interim final rule in the near future that will include a new compliance date of October 1, 2015 for the use of ICD-10. CMS also states that the rule will require HIPAA covered entities to continue to use ICD-9-CM through September 30, 2015. The MLN Connects™ Special Edition eNews also announced the cancelation of the previously…

Read More

CMS PUBLISHES PROVIDER CHARGE & PAYMENT DATA

By | Latest Oncology News | No Comments

4/9/2014 On Wednesday, April 8, the Centers for Medicare and Medicaid Services (CMS), published files detailing 2012 Medicare Part B payments to individual providers and physician practices. The files include what the provider charged as well as Medicare payments by procedure code. The files, which are on the CMS website, provide charge and payment data which CMS states they released in response to demands for transparency. Of concern, is the fact that the data was released without explanation of the Medicare payment system or what the data really shows. This is particularly troublesome for oncology as high cost chemotherapy drugs are shown as having a high revenue rate without mention of the cost of the drugs. In addition, the data is misleading as some revenue that is reported for one provider may be dispersed to other group providers or practices. Since publication of the data, news articles in national publications…

Read More

SGR PATCH UPDATE

By | Latest Oncology News | No Comments

4/1/2014 Congress Passes SGR Patch & ICD-10 Delay On March 31, Congress passed another temporary fix to the flawed sustainable growth rate (SGR) formula. This is the 17th temporary fix to the SGR formula. The bill, Protecting Access to Medicare Act of 2014 (H.R. 4302) is expected to be signed by President Obama and would delay until March 2015 the pending 24% cut to Medicare physician payments. Among other provisions, the bill includes: A 12-month patch for the SGR and continues the 0.5% update through calendar year 2014 and a zero percent payment update from January 1, 2015 to March 31, 2015; An extension of the work GPCI floor until April 1, 2015; A minimum 1-year delay (the bill language states HHS may not adopt ICD-10 as the standard code set until October 1, 2015) in transition from ICD–9 to ICD–10 code sets; The establishment of a market-based payment system…

Read More

SGR PATCH NOW LIKELY

By | Latest Oncology News | No Comments

3/27/2014 SGR and ICD-10 Update During a press conference on Wednesday, House Speaker John Boehner (R-Ohio) announced that a bipartisan, bicameral deal for another 12-month SGR patch was reached and should come up for vote in the House today, Thursday March 27, and then soon thereafter in the Senate. Among other provisions, the proposed bill includes: A 12-month patch for the SGR – freezing the current physician payment rate through March 2015; An extension of the work GPCI floor until April 1, 2015; A 1-year delay in transition from ICD–9 to ICD–10 code sets. With regard to the ICD-10 implementation delay, the bill states, “The Secretary of Health and Human Services may not, prior to October 1, 2015, adopt ICD–10 code sets as the standard for code sets under section 1173(c) of the Social Security Act (42 U.S.C. 1320d–2(c)) and section 162.1002 of title 45, Code of Federal Regulations.” Although…

Read More

REGISTER NOW FOR CMS ICD-10 WEBINAR

By | Latest Oncology News | One Comment

2/10/2014 SGR & Medicare Updates Register now to view the CMS live webcast sessions during the CMS eHealth Summit on ICD-10 on Friday, February 14, 2014, from 9:00 a.m. to 3:30 p.m. ET. The program includes sessions on Readiness from the Provider Perspective, during which providers will discuss their experiences, best practices, tools and resources for the transition to ICD-10, sessions on Readiness from the Vendor, Clearinghouse and Payer Perspective as well as a session on CMS’ Readiness for Provider Coordination. Click Here to view the agenda and register for the webinar. SGR REPEAL BILL GOES TO CONGRESS The bipartisan bill, SGR Repeal and Medicare Provider Payment Modernization Act of 2014 (H.R. 4015/ S. 2000) is advancing to both chambers of Congress. If both the Senate and the House pass the bill, it will go to the President for his signature and the Sustainable Growth Rate (SGR) will immediately be…

Read More

IMPORTANT MEDICARE UPDATES FOR JAN. 1, 2014

By | Latest Oncology News | No Comments

12/31/2013 Physician Payment Cut Averted for 3 Months On Dec. 26, 2013, President Obama signed into law the Pathway for SGR Reform Act of 2013. This law prevents the significant Sustainable Growth Rate (SGR) payment cuts that would have gone into effect on Jan. 1, 2014. The new law provides a 0.5% update for services provided under the Physician Fee Schedule (PFS) for three months. The new payment rate will be in effect from Jan. 1, 2014 through March 31, 2014. Based on this update, the 2014 conversion factor is set at $35.8228. Section 1102 of the new law provides an extension of the Medicare Physician Work Geographic Adjustment Floor – The existing 1.0 floor on the physician work geographic practice cost index (GPCI) is extended through March 31, 2014. As with the physician payment update, this extension will be reflected in the revised 2014 MPFS. The Pathway for SGR…

Read More

GAZYVA BILLING CONSIDERATIONS

By | Latest Oncology News | No Comments

12/16/2013 FDA Approval for GAZVYA Genentech’s GAZYVA (obinutuzumab) is a new FDA-approved anti-CD20 monoclonal antibody indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). The drug comes in a 1,000mg single-dose vial. For Day 1 of Cycle 1 (the first time the patient receives the drug) the patient will only receive 100mg out of the 1,000mg SDV. The remaining 900mg is to be administered on Day 2 of Cycle 1. For subsequent administrations, the indicated dosage will be 1,000mg (the entire SDV) as indicated below: The recommended dose and schedule for the approved regimen is: Obinutuzumab: Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2, and 1000 mg on days 8 and 15. Cycles 2-6: 1000 mg administered intravenously every 28 days Chlorambucil: 0.5 mg/kg orally on days 1 and 15 of each cycle Because this is a…

Read More

EHR DEADLINE APPROACHING

By | Latest Oncology News | No Comments

11/5/2013 Medicare EHR Updates The 2013 meaningful use program year ends on December 31, 2013, and eligible providers (EPs) participating in the Medicare EHR Incentive Program, have until 12:00 am (midnight) Eastern Standard Time on February 28, 2014, to attest to demonstrating meaningful use of the data collected during the reporting period for the 2013 calendar year. CMS reminds EPs that they must attest to demonstrating meaningful use every year in order to receive an incentive and avoid a payment adjustment. Payment adjustments in the EHR program begin on January 1, 2015 for EPs who have not successfully demonstrated meaningful use. More information on the payment adjustment is available in the CMS Payment Adjustment Tip sheet. The payment adjustment is applied to the Medicare Physician Fee Schedule (PFS) amount for covered professional services provided by the EP during the year. The payment adjustment is 1% per year and is cumulative…

Read More

CMS ISSUES 2014 PROPOSED RULES

By | Latest Oncology News | No Comments

7/24/2013 Medicare Proposed Rule 2014 On July 8, 2013 the Centers for Medicare and Medicaid Services (CMS) issued the 2014 proposed rules for the Medicare Physician Fee Schedule (MPFS) and the Hospital Outpatient Prospective Payment System (OPPS). These proposed rules are open for comment until 11:59pm ET, September 6, 2013. There are numerous proposed changes in the MPFS that would affect oncology practices and I urge you to comment on those proposals. However, the comment period allows you enough time to review thoroughly the proposed rule before commenting. In drafting your comments it may be helpful to read comments submitted by other oncology professionals, the proposed rule and submitted comments are available at: www.regulations.gov/#!docketDetail;D=CMS-2013-0155 Oplinc will provide a detailed look at the 2014 Proposed Rules in the next Oplinc Best Practices Review Newsletter sponsored by Lilly. In the meantime, here are some of the highlights of the proposed MPFS. Key…

Read More

OBAMA ADMINISTRATION ANNOUNCES DELAY TO ACA REPORTING REQUIREMENT

By | Latest Oncology News | No Comments

7/5/2013 Delay to ACA Employer Reporting Requirement On Tuesday, July 2, the Obama Administration announced a one-year delay in the Affordable Care Act’s (ACA) mandatory employer and insurer reporting requirements.  The one-year delay in the reporting requirement also effectively delays until 2015 the mandate that businesses with more than 50 employees offer coverage to their workers or pay a penalty, as this penalty is assessed based on the reporting requirement. In a July 2, statement issued by the White House, the Administration announced their intention to simplify the new reporting requirements and provide employers more time to comply with the new rules. The Administration said they would be publishing formal guidance describing the transition, which they say will allow employers the time to test the new reporting systems and make any necessary adaptations to their health benefits while staying the course toward making health coverage more affordable and accessible for…

Read More

NEW FDA APPROVALS

By | Latest Oncology News | No Comments

5/29/2013 Medicare Updates On May 15, 2013, the FDA approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha-particle emitting radiotherapeutic drug which mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover, such as bone metastases.  More Information:  http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352393.htm On May 14, 2013, the FDA approved erlotinib (Tarceva, Astellas Pharma Inc.) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.  This indication for erlotinib is being approved concurrently with the cobas EGFR Mutation Test, a companion diagnostic test for patient selection.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352317.htm CMS PUBLISHES NEW EHR FAQ On 4/26/2013, CMS published the new EHR FAQ #8231, which clarifies the criteria for…

Read More

NEW FDA APPROVALS

By | Latest Oncology News | No Comments

5/29/2013 Medicare Updates On May 15, 2013, the FDA approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha-particle emitting radiotherapeutic drug which mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover, such as bone metastases.  More Information:  http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352393.htm On May 14, 2013, the FDA approved erlotinib (Tarceva, Astellas Pharma Inc.) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.  This indication for erlotinib is being approved concurrently with the cobas EGFR Mutation Test, a companion diagnostic test for patient selection.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352317.htm CMS PUBLISHES NEW EHR FAQ On 4/26/2013, CMS published the new EHR FAQ #8231, which clarifies the criteria for…

Read More

CMS TO CORRECT 96361 EDIT

By | Latest Oncology News | No Comments

5/7/2013 Medicare Denials and eRx Updates CMS Transmittal 2636, Change Request 7501 dated January 16, 2013 provides a list of add-on CPT codes and the primary service codes that they must be performed in conjunction with. The Add-On Code edit file released for April 1, 2013 listed CPT code 96360 (IV infusion, hydration; initial 31 minutes to 1 hour) as the only primary code for add-on code 96361 (each additional hour of hydration). Because of this erroneous edit, practices have been experiencing denials when billing hydration (96361) as a secondary or subsequent service after a different initial service. CMS is taking steps to correct this edit error. In the Add-On Code Edits version for July 1, 2013, CMS will be expanding this list so that the primary codes will be listed as 96360, 96365, 96374, 96409, and 96413. In the meantime, it is suggested that oncologists may choose to delay submission of claims for CPT code 96361…

Read More

CMS TO CORRECT 96361 EDIT

By | Latest Oncology News | No Comments

5/7/2013 Medicare Denials and eRx Updates CMS Transmittal 2636, Change Request 7501 dated January 16, 2013 provides a list of add-on CPT codes and the primary service codes that they must be performed in conjunction with. The Add-On Code edit file released for April 1, 2013 listed CPT code 96360 (IV infusion, hydration; initial 31 minutes to 1 hour) as the only primary code for add-on code 96361 (each additional hour of hydration). Because of this erroneous edit, practices have been experiencing denials when billing hydration (96361) as a secondary or subsequent service after a different initial service. CMS is taking steps to correct this edit error. In the Add-On Code Edits version for July 1, 2013, CMS will be expanding this list so that the primary codes will be listed as 96360, 96365, 96374, 96409, and 96413. In the meantime, it is suggested that oncologists may choose to delay submission of claims for CPT code 96361…

Read More

ICD-10 UPDATE

By | Latest Oncology News | No Comments

5/1/2013 NEW BILL INTRODUCED TO STOP ICD-10 October 1, 2014 is the scheduled implementation deadline for the transition from ICD-9 to the ICD-10 code set.  On Wednesday, April 24, Representative Ted Poe (R-TX) introduced legislation in the U.S. House of Representatives that would stop the replacement of the ICD-9 code set with ICD-10 or any other code set.  H.R. 1701, The Cutting Costly Codes Act, would prohibit the U.S. Department of Health and Human Services from implementing, administering or enforcing current regulations that require the new code set to take effect. The bill also calls for a federal study to identify ways to mitigate disruptions caused by any replacement of the ICD-9 code set. In a letter of support to Poe, the AMA states that they remain deeply concerned about the timing of the ICD-10 transition during a time when physicians are devoting significant time and resources towards implementing EHRs…

Read More

NEW BILL INTRODUCED TO STOP ICD-10

By | Latest Oncology News | No Comments

5/1/2013 ICD-10 UPDATE October 1, 2014 is the scheduled implementation deadline for the transition from ICD-9 to the ICD-10 code set.  On Wednesday, April 24, Representative Ted Poe (R-TX) introduced legislation in the U.S. House of Representatives that would stop the replacement of the ICD-9 code set with ICD-10 or any other code set.  H.R. 1701, The Cutting Costly Codes Act, would prohibit the U.S. Department of Health and Human Services from implementing, administering or enforcing current regulations that require the new code set to take effect. The bill also calls for a federal study to identify ways to mitigate disruptions caused by any replacement of the ICD-9 code set. In a letter of support to Poe, the AMA states that they remain deeply concerned about the timing of the ICD-10 transition during a time when physicians are devoting significant time and resources towards implementing EHRs and participating in numerous…

Read More

SEQUESTRATION CUTS & MEDICARE

By | Latest Oncology News | No Comments

4/14/2013 Medicare Reimbursement Updates On April 9, Representative Renee Ellmers (R-N.C.) introduced the Cancer Patient Protection Act of 2013. This bill seeks to reverse the sequester cuts that are being applied to physician administered cancer care drugs. Beginning on April 1, 2013, the 2% sequestration reduction on Medicare physician payments is being applied to physician services and physician administered drugs. The application of the 2% cut to the reimbursement rate for cancer care drugs have forced some cancer clinics to stop treating Medicare patients. Passage of legislation is necessary to stop the cuts to cancer care, as CMS has stated that they do not have the authority to do so. Representative Ellmers’ bill also requires the retroactive restoration of payments on cancer care drugs that were reduced by the sequestration cuts. STOP THE CUTS TO CANCER CARE If you have not yet contacted your legislators, please take a moment to…

Read More

SEQUESTRATION CUTS & MEDICARE

By | Latest Oncology News | No Comments

3/8/2013 2% Medicare Cuts Effective April 1 On Friday, March 8 CMS published a listserv message regarding the pending sequestration cuts and their impact on Medicare Part A and Part B fee-for-service (FFS) payments. CMS reports that Medicare FFS claims with dates-of-service or dates-of-discharge on or after April 1, 2013, will incur a 2% reduction in Medicare payment. The 2% reduction in payment will also apply to claims for durable medical equipment (DME) and supplies, including claims under the DME Competitive Bidding Program when the date-of-service, or the start date for rental equipment or multi-day supplies, is on or after April 1, 2013. CMS explains that the 2% claims payment adjustment will be applied to all claims after determining coinsurance, any applicable deductible, and any applicable Medicare Secondary Payment adjustments. Therefore, beneficiary payments for deductibles and coinsurance are not subject to the 2% payment reduction. The sequestration cuts are part…

Read More

NEULASTA RAC AUDITS

By | Latest Oncology News | No Comments

11/19/2012 Medicare Updates HealthDataInsights (HDI), the Recovery Audit Contractor (RAC) for Region D (AK, AZ, CA, HI, IA, ID, KS, MO, MT, ND, NE, NV, OR, SD, UT, WA, and WY) has been auditing payments for pegfilgrastim (Neulasta) and requesting repayment if this medication was administered on the same day as chemotherapy for claims dating back to 2009. Several state societies including WA, OR, ID, AZ, CA, UT and AK have been working with Noridian, CMS and ASCO to try to get these audits stopped. Last week, the WA state society was informed that the RAC audits on same day Neulasta have been halted. We are awaiting the publication of an article on the administration of Neulasta on the same day as chemotherapy, and will provide that information as soon as it is available. Nevertheless, it is very important that you continue to respond promptly to all RAC requests you…

Read More

CDC ISSUES WARNS AGAINST USING SDVs FOR MULTIPLE PATIENTS

By | Latest Oncology News | No Comments

7/14/2012 CDC ISSUES WARNS AGAINST USING SDVs FOR MULTIPLE PATIENTS On July 13, the Centers for Disease Control (CDC) released a report detailing recent instances of improper reuse of single-dose vials (SDVs) for more than one patient that resulted in two outbreaks of invasive staphylococcus aureus infection. In the report, the CDC states, “Proper use of SDVs in clinical settings consists of 1) withdrawing contents into a new sterile syringe in an aseptic manner, 2) promptly using the contents for a single patient during a single procedure, and 3) disposing of the vial and any remaining contents. To prevent unsafe practices and patient harm, CDC recently issued a communication clarifying recommended practices for safe use of SDVs (1). The safest option remains dedicating SDVs to individual patients. When individually packaged and appropriately sized SDVs are unavailable, qualified health-care personnel may repackage medication from a previously unopened SDV into multiple single-use…

Read More

OPLINC’S BEST PRACTICES REVIEW NEWSLETTER NOW AVAILABLE AS AN iBOOK

By | Latest Oncology News | No Comments

4/6/2012 OPLINC’S BEST PRACTICES REVIEW NEWSLETTER NOW AVAILABLE AS AN iBOOK The Oplinc Best Practices Review Newsletter, sponsored by Lilly Oncology is now available to download as an iBook on your iPad. To download to your iPad go to www.Oplinc.com, click on the “View Latest Best Practices Review” link. To sign up for the complimentary Best Practices Review newsletter Click Here. Are you an Oncology Supply customer? If so, watch your drug shipments for the print copy of the Best Practices Review newsletter.

Read More